Study details
Enrolling now
Anti Inflammatory Lipid Mediators in Asthma
University of Colorado, Denver
NCT IDNCT03762395ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
60
Study length
about 7 years
Ages
18–65
Locations
1 site in CO
What this study is about
This trial is testing a treatment called CXA-10 to see if it helps people with asthma and obesity. The goal is to determine if CXA-10 reduces inflammation in the lungs, which can worsen asthma symptoms.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take CXA-10
- 2.Take Matching Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Changes in pre-bronchodilator FEV1 per spirometry
Body systems
Endocrinology, Respiratory